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ABSTRACT
Pneumonia often occurs as secondary infection post influenza disease and accounts for a large proportion of the morbidity and 
mortality associated with seasonal and pandemic influenza outbreaks. The antiviral drug triazavirine is licensed in Russia for the 
treatment and prophylaxis of acute respiratory infections, including influenza A and B viruses. In the present study, we investi-
gated the efficacy of triazavirine in a mouse model of secondary Staphylococcus aureus pneumonia following A/California/04/2009 
(H1N1)pdm09 influenza virus infection. We also performed a study of the efficacy of triazavirine against the A/California/04/2009 
(H1N1)pdm09 lethal influenza infection in mice. In this model, triazavirine at the dose of 25 mg/kg/day significantly enhanced 
the survival of animals (60% compared to 20%) and the mean survival time to death, prevented weight loss, and reduced viral titer 
in the lungs of mice infected with influenza virus. At doses of 50 and 100 mg/kg/day, triazavirine was highly effective in the treat-
ment of the secondary bacterial pneumonia following influenza infection in mice. At these doses, triazavirine protected 67-75% of 
animals against death, increased the mean survival time to death by twofold, and reduced the virus titer by 2.2-3.0 log10TCID50/ml 
compared to the mice in the control group. These findings suggest the possible benefit of triazavirine treatment in reducing post 
influenza pneumonia incidence in humans. 
INTRODUCTION
Influenza is an infectious disease that causes harm to hu-
man health and inflicts huge economic losses. Influenza 
mortality rates in different age groups vary from tens to 
hundreds of cases during epidemics and comprise up to 
1,000 cases per 100,000 people during pandemics [1, 2, 
3]. The majority of influenza-associated deaths are due 
to secondary bacterial complications with pneumonia 
being the major cause. 200 million of the 429.2 million 
cases of pneumonia reported annually are those that oc-
curred following acute respiratory viral infections (ARVIs) 
including influenza with 3 to 4 million lethal outcomes 
(7% of overall mortality) [2, 4]. Approx. 43-67% of pneu-
monia cases following ARVIs are reported for children 
under 5 years old putting them at particular risk [5]. The 
prevalence of pneumonia is shown to increase following 
influenza epidemics/pandemics. Therefore, a significant 
increase in the pneumonia mortality rate was recorded 
during the pandemics of 1918, 1957, 1968, and 2009 [5, 6]. 
The histological and microbiological examination of au-
topsy samples taken from individuals who died during 
the 1918 Spanish influenza pandemic revealed that the 
majority of the deaths were caused by secondary pneu-
monia. Streptococcus pneumoniae (S.  pneumoniae) and 
Staphylococcus aureus (S. aureus) are the most common 
etiological agents at secondary pneumonias. The analy-
sis of clinical data showed that bacterial pneumonias 
account for 30% of complications following pandemic 
influenza virus A/California/07/2009 (H1N1)pdm09 in-
fection, with S. aureus being the most frequently report-
ed disease-causing agent [7, 8]. Prevention and proper 
treatment of influenza infection seem to be the best 
strategy to reduce secondary complications from influ-
enza. In particular, it was found that influenza vaccina-
tion reduces hospital admissions due to pneumonia in 
elderly individuals and the use of anti-influenza drugs 
to treat the infection lowers the rate of further bacterial 
complications [5]. The same effect was shown in an ex-
perimental model for the secondary bacterial pneumonia 
following influenza infection [9-11]. The use of oselta-
mivir, a neuraminidase inhibitor, in mice infected with 
influenza A virus and later with S. pneumoniae, reduced 
the mortality due to secondary bacterial pneumonia de-
veloped following the influenza infection, decreased the 
disease symptoms, and facilitated the course of the in-
fection [12]. Similar results were obtained with fludaza 
(NeoBix, USA), a drug undergoing phase III clinical trials, 
and with umifenovir, an anti-influenza drug licensed by 
Pharmstandard (Russia) [13, 14].
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The novel original drug that belongs to the azoloazine 
class of compounds, triazavirine (an analogue of purine 
nucleotide guanine), is licensed in Russia [15]. This drug 
was developed jointly by the scientists of Ural State Poly-
technic University (Ekaterinburg, Russia), Postovsky In-
stitute of Organic Synthesis (Ekaterinburg, Russia), and 
Research Institute of Influenza (St. Petersburg, Russia). 
Тriazavirine has a broad spectrum of antiviral activity 
and is effective against a number of acute respiratory 
virus infections, including influenza A and B. The goal 
of this project was to study the efficacy of triazavirine 





1,2,4-triazine-7(4I´)-one) was provided by Medsynthesis 
(Russia) (Fig. 1A) [15]. 
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Fig. 1. Structure of triazavirine (A), oseltamivir phosphate (B) and 
umifenovir (C)
Oseltamivir phosphate (Ethyl (3R,4R,5S)-4-acetami-
do-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-car-
boxylate phosphate) (Fig. 1B)  was a gift from Chemical 
Diversity, Inc. (San-Diego, USA). Umifenovir (Ethyl 6-bro-
mo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-
[(phenylthio)methyl)]-1H-indole-3-carboxylate) (Fig. 1C) 
was provided by Pharmstandard (Russia). Oseltamivir 
phosphate and triazavirine were dissolved in sterile dis-
tilled water. For the oral delivery to mice, umifenovir was 
suspended in 1% starch solution. For each experiment, 
the freshly made solutions of drugs were used.
Cells and influenza viruses 
Madin Darby canine kidney (MDCK) cells were grown 
at 37°C in a humidified atmosphere of 5% CO2 in mini-
mal essential medium (MEM) supplemented with 10% 
fetal bovine serum (FBS), 5  mM L-glutamine, 25  mM 
HEPES, 100 U/ml penicillin, 100 μg/ml streptomycin sul-
fate, and 100  μg/ml kanamycin sulfate. Influenza virus 
A/California/04/2009 (H1N1)pdm09 (A/CA/04/09) was 
provided by the WHO collaborating Center - Research 
Institute of Influenza (St. Petersburg, Russia). The virus 
was propagated in embryonated chicken eggs (CE). The 
virus infectious titer was determined by titration in CE 
and expressed as a decimal logarithm of embryonated 
infectious doses (log10EID50/ml). The strain S. aureus 1986 
was obtained from the collection of the Mechnikov In-
stitute for Vaccines and Sera (Moscow, Russia). Bacteria 
were propagated on tryptic soy agar. 
Assessment of drug efficacy in mouse models
Female BALB/c mice that were obtained from the Scien-
tific Center of Biomedical Technologies of the Russian 
Academy of Science (Andreevka, Moscow region, Russia) 
weighing approximately 12 to 14 g were quarantined and 
acclimated for 3 days prior to use. Mice were housed in 
cages and used for treatment in groups of 13 animals. All 
the studies were approved by the Mechnikov Research 
Institute of Vaccines and Sera Committee on the Ethics 
of Animal Experiments and were conducted in strict ac-
cordance with the applicable laws and guidelines.
For animal infection mouse-adapted A/CA/04/09 vi-
rus was obtained by 3 subsequent passages in mouse 
lungs. In order to study the efficacy of drugs against 
influenza infection mice were intranasally (i.n.) chal-
lenged with mouse lethal dose (MLD80/0.1 ml), which 
is equal to 4.0  log10EID50/0.1 ml) of A/CA/04/09 virus. 
In the experiments dealing with secondary bacterial 
pneumonia following influenza, the animals were in-
fected i.n. with 0.5  MLD50/0.1 ml of mouse-adapted 
A/CA/04/09 virus. S. aureus stocks were grown overnight 
in tryptic soy broth at 37°C and diluted in sterile PBS to 
2x1010 of colony forming units (CFU/0.1 ml) prior to use. 
S. aureus challenge was performed i.n. on day 4 after the 
virus infection. Prior to the intranasal delivery of infec-
tious agents, the animals were lightly anesthetized by 
ether. 
In all our experiments, antivirals were administered 
to mice intragastrically (i.g.) by oral gavage in the volume 
of 200 μl. Triazavirine was administered for 5 consecu-
tive days starting from 24 h before the viral inoculation 
in the dose of 25, 50, or 100 mg/kg/day of mouse body 
weight twice a day. Umifenovir served as a positive con-
trol and was administered for 5 consecutive days starting 
24 h before viral inoculation in the dose of 60 mg/kg/day 
once per day (in the morning). Oseltamivir was used as 
a second positive control and was administered 6 h be-
fore viral inoculation in the dose of 10 mg/kg/day and for 
5 consecutive days twice a day. Animals of the placebo 
group were treated by PBS. From day 0 to day 15 post 
infection (p.i.), the animals were weighed and the weight 
loss/gain was calculated for each mouse as a percentage 
of body weight to day 0 before the virus inoculation. The 
reported values are expressed as mean value ± standard 
deviation (SD). Animals that showed signs of severe dis-
ease and weight loss of  ≥  25% were humanely eutha-
nized. The survival rate of the animals was monitored 
for 21 days. The efficacy of the corresponding antiviral 
agent was determined according to the number of mice 
that survived 21 days post infection, the mean number 
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of days to death, and weight loss. The mean survival day 
(MSD) was calculated by the formula: MSD=[f(d-1)]/n, 
where f is the number of the mice that survived at day d, 
and n is the total number of mice in the group.
Lung examination
3  mice from each group were euthanized at the 4th or 
7th day post-viral infection from the groups infected 
only with virus and with both the virus and bacteria, re-
spectively. The viral titers and bacterial counts were es-
timated in the lungs. The lung homogenates were pre-
pared, spun at 10 g for 5 min, and the supernatants were 
used for the determination of virus titers and/or bacterial 
counts. Quantification of the S. aureus colonies was done 
in tenfold dilutions of lung supernatant added to tryp-
tic soy agar plates supplemented with 3% sheep eryth-
rocytes (vol/vol). Identification of the colonies was done 
by visual inspection. Virus titers were determined by the 
titration of lung homogenates on MDCK cell monolayers 
and expressed as a decimal logarithm of the tissue cul-
ture infectious doses (log10TCID50/ml).
RESULTS
Efficacy of triazavirine in mice infected 
with influenza virus
As it was shown earlier [16], without prior adaptation in-
fluenza virus A/CA/04/09 does not kill mice but causes a 
transient weight reduction (up to 11%). Therefore, the 
virus A/CA/04/09 was first adapted to mice by consecu-
tive passages in the mouse lungs, and then was used in 
experiments to estimate the efficacy of the antivirals. In 
the first set of experiments, we studied the efficacy of 
triazavirine in mice infected with the MLD80 of mouse-
adapted A/CA/04/09 virus. Two antiviral drugs with a 
different mechanism of action – neuraminidase inhibi-
tor oseltamivir and fusion inhibitor umifenovir – were 
used as the controls. A high mortality rate (80%) and 
loss of body weight (10%) were observed after the viral 
infection in the control group of mice that were place-
bo treated (PBS) (Fig. 2 A, B). Of the three triazavirine 
dose regimens (25, 50, and 100 mg/kg/day), only the first 
one significantly enhanced the survival of animals (60% 
vs. 20%, p <0.05) in comparison to the placebo control 
group (Fig. 2A). Administration of triazavirine at 25 mg/
kg/day also resulted in the enhancement of the mean 
survival time to 12.8 days compared to 10 days for the 
placebo treated control group of mice. Triazavirine at 
dose of 50 mg/kg/day provided the survival rate of 45%, 
which was not significantly different from that of the 
placebo control group. The survival rate and a mean sur-
vival time for the group of mice treated with 100 mg/kg/
day of triazavirine did not differ from that of the mice in 
the control group. The animals in all the infected mouse 
groups after the treatment demonstrated weight loss as 
well as mice in the placebo treated group. However, in 
the group of animals that was treated with triazavirine 
at 25 mg/kg/day the increase of body weight observed 
starting from day 7 p.i. (Fig. 2B). 
A
B
Fig. 2. The effect of antiviral drugs administration on survival rates 
(A) and weight loss (B) of mice infected with the mouse-adapted 
A/CA/04/09 virus. (*) The difference is significant when compared 
to the group of placebo control, Mantel-Cox test, p < 0.05.
The most profound therapeutic effect was observed 
for oseltamivir at 10 mg/kg/day and umifenovir at 60 mg/
kg/day. The administration of these antivirals completely 
protected the infected mice from death and prevented 
their weight loss (Fig. 2A, B).
The virus titers in the lungs of mice were measured 
at day 4 p.i. and are shown in Fig. 3. The corresponding 
virus titers for animals from the group treated with tri-
azavirine at dose 25 mg/kg/day were significantly lower 
compared to those for the placebo control group (2.8±1.0 
vs 5.2±0.6, p < 0.05, respectively). Treatment of mice with 
triazavirine at doses of 50 and 100 mg/kg/day, as well as 
with umifenovir and oseltamivir did not result in statisti-
cally signifucant reduction of viral titers in lungs (Fig. 3). 
Fig. 3. Viral titers in the lungs of infected mice treated with anti-
virals on day 4 post influenza virus infection. The results are pre-
sented as M ± SD. (*) The difference is significant when compared 
to the group of placebo treated control, Student’s t-test, p < 0.05.
Efficacy of triazavirine in the model of secondary 
bacterial pneumonia following influenza infection 
In the next set of experiments, we studied the effect of 
triazavirine treatment on mice that were first infected 
with influenza virus and 4 days later challenged with 
S. aureus. In these experiments, we infected the animals 
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with a sublethal dose 0.5  MLD50 of the mouse-adapted 
influenza virus A/CA/04/09 or mock-infected them with 
PBS and 4 days later challenged the same groups of mice 
with 2x1010 CFU of S. aureus. The virus infection at this 
dose did not cause the death of animals in the virus con-
trol group (infected with the virus only). In the bacterial 
control group (exposed to intranasal infection with S. au-
reus only), no deaths were reported as well. All mice in-
fected with the virus followed by the infection with bac-
teria died in 11/7 days after the virus/bacterial challenge, 
respectively (Fig. 4A). The combined infection with both 
pathogens also resulted in significant weight loss (almost 
30% on study day 9) (Fig.  4B). The obtained data were 
confirmed by lung examination. Bacterial co-infection 
with S. aureus of virus infected mice led to significantly 
increased viral lung titers (Table). The bacterial densi-
ties in the lungs of mice pre-infected with influenza virus 
were not significantly different compared to the mock-
infected mice (Table). 
A
B
Fig. 4. The effect of antiviral drugs on survival rates (A) and weight 
loss (B) in mice infected with the mouse-adapted A/CA/04/09 virus 
followed by infection with S. aureus 1986. (*) The difference is sig-
nificant when compared to the group of placebo control, Mantel-
Cox test, p < 0.05, (**) indicates p < 0.001.
Triazavirine showed the dose dependent efficacy in 
the treatment of mice with the secondary bacterial pneu-
monia following influenza infection. The administration 
of this drug at 25 mg/kg/day gave a poor effect on the sur-
vival rate (25%) and weight loss, but increased the mean 
survival time. The density of bacteria and the virus titer in 
animals treated with triazavirine at this low dose did not 
significantly differ from that in the placebo control group 
of animals (Table). The administration of triazavirine to 
mice in doses of 50 and 100 mg/kg/day was more effec-
tive. This treatment resulted in significantly enhanced 
survival of 67-75% of the animals (p<0.001) and increased 
the time to death by more than twofold, compared to the 
virus infected mice co-infected with S. aureus (Fig.4 A). 
These results correlate to the outcome of the lung ex-
amination experiments. The administration of triaza-
virine at 50 and 100 mg/kg/day significantly reduced the 
virus titer by 2.2 and 3.0  log10TCID50/ml respectively in 
the treated animals (p < 0.001). No significant reduction 
of the bacterial counts in the lungs of the animals co-
infected with mouse-adapted A/CA/04/09 and S. aureus 
was noticed (Table). Similar results were observed in the 
group treated by umifenovir at 60 mg/kg/day, which pro-
tected 67% of the mice (p < 0.001) and increased the time 
to death up to 16.3 days. However, umifenovir did not re-
duce significantly the virus titer and the density of the 
bacteria in the lungs of infected animals. The treatment 
with another antiviral drug, oseltamivir at 10 mg/kg/day, 
of animals infected with influenza A/CA/04/09 virus fol-
lowed by infection with S.  aureus protected 42% of the 
animals against death (p < 0.05), and increased the time 
to death by 1.5 times on average (Fig. 4. A, B). At the same 
time, the treatment with oseltamivir did not decrease the 
virus titer, but significantly reduced the density of the 
bacteria in mouse lungs (p < 0.001, Table). 
DISCUSSION
Pneumonia often occurs as a complication after the in-
fluenza infection and accounts for a large proportion of 
the morbidity and mortality associated with seasonal and 
pandemic influenza outbreaks [5, 7]. Antibiotic therapy 
alone may not be the most efficacious treatment for this 
dual infection. However, antiviral therapy has often been 
ignored because viral infections are usually resolved by 
Table. The effect of antiviral drugs administration on the mean time to death, viral titer, and bacterial density in the lungs.
Treatment MSD Virus titer in the lungs 
at day 4 p.i., log10TCID50/ml
a
Bacterial density in the lungs,
CFU/mla
1. A/CA/04/09 + S. aureus + triazavirine 25 mg/kg/day 
2. A/CA/04/09 + S. aureus + triazavirine 50 mg/kg/day 
3. A/CA/04/09 + S. aureus + triazavirine 100 mg/kg/day 
4. A/CA/04/09 + S. aureus + oseltamivir 10 mg/kg/day
5. A/CA/04/09 + S. aureus + umifenovir 60 mg/kg/day



























a The data are given as M ± SD.
(†) The difference is significant when compared to the group infected with the virus A/CA/04/09 alone, Student’s t-test, p < 0.001. 
(*) The difference is significant when compared to the group of virus infected mice and co-infected with S. aureus, Student’s t-test, p < 0.001.
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the time the bacterial pneumonia occurs. It was shown 
previously that antiviral treatment with oseltamivir and 
umifenovir improves the outcome of the secondary bac-
terial pneumonia after influenza in the mouse model 
[12-14]. Clinical trials have also confirmed this effect and 
showed that the antiviral treatment of influenza reduces 
the risk of post influenza complications [16].
In the present study, the antiviral compound triaza-
virine was tested in a mouse model of secondary bacterial 
pneumonia after influenza compared to the mouse model 
of influenza pneumonia. Treatment with triazavirine in 
the mouse lethal model of influenza was not highly effec-
tive and only at the lowest dose 25 mg/kg/day led to a sta-
tistically significant improvement of the animals’ survival 
rate and extension of mean survival time. The adminis-
tration of triazavirine at this dose also prevented weight 
loss in the infected animals. Efficacy of triazavirine treat-
ment decreased with the increase of the drug dose and at 
100 mg/kg/day – the highest of the studied doses – triaza-
virine was not effective at all in this model. 
The efficacy of triazavirine treatment in a mouse mod-
el of secondary bacterial pneumonia after influenza was 
more effective and increased along with increasing the 
drug dose. The administration of triazavirine at the doses 
50 and 100  mg/kg/day in our experiments significantly 
decreased the virus titer and increased the survival post 
the secondary bacterial pneumonia following influenza 
in mice.  The effectiveness of triazavirine was not infe-
rior to licensed drugs oseltamivir and umifenovir. One of 
the possible explanations of the significant difference ob-
served in experiments with these two models could be the 
narrow therapeutic window in infected mice in the first 
model. Clinical trials showed that triazavirine is well tol-
erated and safe in humans. Experimental studies revealed 
that triazavirine has low toxicity in animals including 
mice (unpublished data). However, it is known that the 
toxicity of some drugs is significantly higher in infected 
versus intact animals. Since, in the lethal model, the in-
fluenza pneumonia is acute and fast-paced, the therapeu-
tic effect of the drug at high doses could be masked due 
to the drug toxicity. That effect could be the reason for a 
contradictory outcome of the experiments using this drug 
in two different models. For simulation of the secondary 
bacterial pneumonia after influenza in mice we used the 
sublethal dose of virus. In that case, the viral infection de-
velops slowly and is less harmful for the infected animals 
and that makes the effect of the drug more pronounced. 
The difference observed in the experiments with tri-
azavirine in two models could also be explained by the 
mechanism of action of this drug. As it was shown pre-
viously [15], triazavirine, being a guanine analogue, is 
a selective inhibitor of influenza RNA polymerase com-
plexes. In addition, there are some data about its pleio-
tropic mechanism of action. It was shown that triaza-
virine affects the formation of amyloid-like fibrils of the 
model peptide (SI), which determines the pathogenesis 
of conformational diseases [17]. Moreover, amyloid-like 
oligomers can also act as signal transducers in healthy 
and infected organisms [18]. 
The influenza-bacterial co-infection is a multifacto-
rial process that involves various pathogenic factors of 
virus and bacteria as well as host responses. All of these 
factors should be taken into account when considering 
the incidence and pathogenicity of these co-infections. 
Experiments in animal models have improved our un-
derstanding of how influenza viruses interact with their 
bacterial co-pathogens and of the accompanying host 
immune response. The results of these experiments 
showed that aberrant immune response leads to severe 
inflammation, a key driver of bacterial acquisition and 
infection severity following influenza [5, 11]. 
Therefore, the use of antivirals like triazavirine, which 
suppress virus replication and significantly increase the 
survival of animals with a combined virus – bacterial in-
fection could decrease the severity of a secondary bac-
terial infection of the host organism, and it could be a 
new method to prevent and treat influenza-associated 
bacterial co-infections. Further studies are necessary to 
confirm this effect in humans.
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